View Item 

Show simple item record

Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis
dc.contributor.authorNagaraja, Vivek
dc.contributor.authorMatucci‐cerinic, Marco
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorKuwana, Masataka
dc.contributor.authorAllanore, Yannick
dc.contributor.authorDenton, Christopher P.
dc.contributor.authorRaghu, Ganesh
dc.contributor.authorMclaughlin, Vallerie
dc.contributor.authorRao, Panduranga S.
dc.contributor.authorSeibold, James R.
dc.contributor.authorPauling, John D.
dc.contributor.authorWhitfield, Michael L.
dc.contributor.authorKhanna, Dinesh
dc.date.accessioned2020-07-02T20:34:43Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-07-02T20:34:43Z
dc.date.issued2020-07
dc.identifier.citationNagaraja, Vivek; Matucci‐cerinic, Marco ; Furst, Daniel E.; Kuwana, Masataka; Allanore, Yannick; Denton, Christopher P.; Raghu, Ganesh; Mclaughlin, Vallerie; Rao, Panduranga S.; Seibold, James R.; Pauling, John D.; Whitfield, Michael L.; Khanna, Dinesh (2020). "Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis." Arthritis & Rheumatology 72(7): 1049-1058.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/155996
dc.publisherWiley Periodicals, Inc.
dc.titleCurrent and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155996/1/art41246_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155996/2/art41246.pdf
dc.identifier.doi10.1002/art.41246
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes- Elstein L, et al. Short- term progression of interstitial lung disease in systemic sclerosis predicts long- term survival in two independent clinical trial cohorts. Ann Rheum Dis 2019; 78: 122 - 30.
dc.identifier.citedreferenceSullivan K, Pinckney A, Goldmuntz E, Welch B, Khanna D, Simms RW, et al. Myeloablative autologous hematopoietic stem cell transplantation for severe scleroderma: long- term outcomes 6- 11 years after entry on a randomized study comparing transplantation and cyclophosphamide [abstract]. Arthritis Rheumatol 2018; 70 Suppl 9. URL: https://acrab- strac- ts.org/abstr- act/myelo- ablat- ive-autol- ogous-hemat- opoie- tic-stem-cell-trans- plant- ation-for-severe-scler- oderma-long-term-outco- mes-6-11-years-after-entry-on-a-rando- mized-study-compa- ring-trans- plant- ation-and-cyclo- phosp- hamid- e/.
dc.identifier.citedreferencePoormoghim H, Lucas M, Fertig N, Medsger TA. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty- eight patients. Arthritis Rheum 2000; 43: 444 - 51.
dc.identifier.citedreferenceShand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422 - 31.
dc.identifier.citedreferenceNamas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post- hoc analyses from two randomized placebo- controlled trials. Arthritis Care Res (Hoboken) 2018; 70439 - 44.
dc.identifier.citedreferenceKhanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase 2 investigator- initiated, multicenter, double- blind randomized placebo- controlled trial. Arthritis Rheumatol 2020; 72125 - 36.
dc.identifier.citedreferenceKhanna D, Lin CJ, Kuwana M, Allanore Y, Batalov A, Butrimiene I, et al. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]. Arthritis Rheumatol 2018; 70 Supple 10. URL: https://acrab- strac- ts.org/abstr- act/effic- acy-and-safety-of-tocil- izumab-for-the-treat- ment-of-syste- mic-scler- osis-resul- ts-from-a-phase-3-rando- mized-contr- olled-trial/.
dc.identifier.citedreferenceLaunay D, Remy- Jardin M, Michon- Pasturel U, Mastora I, Hachulla E, Lambert M, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33: 1789 - 801.
dc.identifier.citedreferenceHoa S, Bernatsky S, Steele RJ, Baron M, Hudson M. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology (Oxford) 2019. E- pub ahead of print.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma- related interstitial lung disease (SLS II): a randomised controlled, double- blind, parallel group trial. Lancet Respir Med 2016; 4: 708 - 19.
dc.identifier.citedreferenceSircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 2018; 57: 2106 - 13.
dc.identifier.citedreferenceKhanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630 - 40.
dc.identifier.citedreferenceDistler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis- associated interstitial lung disease. N Engl J Med 2019; 380: 2518 - 28.
dc.identifier.citedreferenceKahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006; 45 Suppl 4: iv14 - 7.
dc.identifier.citedreferenceForbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii36 - 9.
dc.identifier.citedreferenceHerrick AL, Gallas A. Systemic sclerosis- related calcinosis. J Scleroderma Relat Disord 2016; 1: 194 - 203.
dc.identifier.citedreferenceAvouac J, Walker U, Tyndall A, Kahan A, Matucci- Cerinic M, Allanore Y, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010; 37: 1488 - 501.
dc.identifier.citedreferenceClements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high- dose versus low- dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001; 44: 653 - 61.
dc.identifier.citedreferenceGhrénassia E, Avouac J, Khanna D, Derk CT, Distler O, Suliman YA, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case- control study. J Rheumatol 2014; 41: 99 - 105.
dc.identifier.citedreferenceDistler O, Allanore Y, Denton C, Kuwana M, Matucci- Cerinic M, Pope J, et al. OP0183 Efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis and interstitial lung disease (SSc- ILD): results from the Phase IIb RISE- SSc Study. Ann Rheum Dis 2019; 78: 167.
dc.identifier.citedreferenceSitbon O, Gomberg- Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801908.
dc.identifier.citedreferenceVan Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554 - 61.
dc.identifier.citedreferenceKhanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud’s condition score in patients with Raynaud’s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69: 588 - 91.
dc.identifier.citedreferencePauling JD, Reilly E, Smith T, Frech TM. Factors influencing Raynaud’s condition score diary outcomes in systemic sclerosis. J Rheumatol 2019; 46: 1326 - 34.
dc.identifier.citedreferenceSteen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient- generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984 - 91.
dc.identifier.citedreferenceBenza RL, Gomberg- Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS- based risk assessment strategies. Chest 2019; 156: 323 - 37.
dc.identifier.citedreferenceDenton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685 - 99.
dc.identifier.citedreferenceAllanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers 2015; 1: 15002.
dc.identifier.citedreferenceVarga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017; 2: 137 - 52.
dc.identifier.citedreferenceNihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109 - 15.
dc.identifier.citedreferenceElhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir- Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897 - 905.
dc.identifier.citedreferenceSullivan KM, Goldmuntz EA, Keyes- Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem- cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35 - 47.
dc.identifier.citedreferenceVan Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490 - 8.
dc.identifier.citedreferenceBurt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non- myeloablative haemopoietic stem- cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open- label, randomised phase 2 trial. Lancet 2011; 378: 498 - 506.
dc.identifier.citedreferenceNash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, et al. High- dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long- term follow- up of the US multicenter pilot study. Blood 2007; 110: 1388 - 96.
dc.identifier.citedreferenceSmolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023 - 38.
dc.identifier.citedreferenceSt. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432 - 43.
dc.identifier.citedreferenceVan den Hombergh WM, Carreira PE, Knaapen- Hans HK, van den Hoogen FH, Fransen J, Vonk MC. An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto- antibodies: derivation and validation. Rheumatology (Oxford) 2016; 55: 2023 - 32.
dc.identifier.citedreferenceVan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737 - 47.
dc.identifier.citedreferenceMinier T, Guiducci S, Bellando- Randone S, Bruni C, Lepri G, Czirják L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014; 73: 2087 - 93.
dc.identifier.citedreferenceWirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, et al. Incidence and predictors of cu taneous manifestations during the early course of systemic sclerosis: a 10- year longitudinal study from the EUSTAR database. Ann Rheum Dis 2016; 75: 1285 - 92.
dc.identifier.citedreferenceSteen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437 - 44.
dc.identifier.citedreferenceLeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202 - 5.
dc.identifier.citedreferenceWalker UA, Tyndall A, Czirjak L, Denton C, Farge- Bancel D, Kowal- Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754 - 63.
dc.identifier.citedreferenceMerkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta- analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012; 64: 3420 - 9.
dc.identifier.citedreferenceHachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211 - 9.
dc.identifier.citedreferenceBhattacharyya S, Midwood KS, Yin H, Varga J. Toll- like receptor- 4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma. Adv Wound Care (New Rochelle) 2017; 6: 356 - 69.
dc.identifier.citedreferenceMilano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.
dc.identifier.citedreferenceTyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809 - 15.
dc.identifier.citedreferenceSteen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972- 2002. Ann Rheum Dis 2007; 66: 940 - 4.
dc.identifier.citedreferenceElhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta- analysis of cohort studies [review]. Rheumatology (Oxford) 2012; 51: 1017 - 26.
dc.identifier.citedreferenceHinchcliff M, Huang CC, Wood TA, Mahoney JM, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979 - 89.
dc.identifier.citedreferenceMartyanov V, Whitfield ML. Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data [review]. Curr Opin Rheumatol 2016; 28: 83 - 8.
dc.identifier.citedreferenceNevskaya T, Baron M, Pope JE. Canadian Scleroderma Research Group. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. Rheumatology (Oxford) 2017; 56: 111 - 22.
dc.identifier.citedreferenceNihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett- Smith EC, Fonseca C, et al. Using autoantibodies and cutaneous subset to develop outcome- based disease classification in systemic sclerosis. Arthritis Rheumatol 2020; 72: 465 - 76.
dc.identifier.citedreferencePrevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty- eight- joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44 - 8.
dc.identifier.citedreferenceAletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796 - 806.
dc.identifier.citedreferenceClements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281 - 5.
dc.identifier.citedreferenceKhanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, et al. The American College of Rheumatology Provisional Composite Response Index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2016; 68: 299 - 311.
dc.identifier.citedreferenceFries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137 - 45.
dc.identifier.citedreferenceAllanore Y. Limited cutaneous systemic sclerosis: the unfairly neglected subset [editorial]. J Scleroderma Relat Disord 2016; 1: 241 - 6.
dc.identifier.citedreferenceBaron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, et al. An interim report of the scleroderma clinical trials consortium working groups. J Scleroderma Relat Disord 2019; 4: 17 - 27.
dc.identifier.citedreferenceMihai C, Landewe R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 2016; 75: 681 - 6.
dc.identifier.citedreferenceMatucci- Cerinic M, Kahaleh B, Wigley FM. Evidence that systemic sclerosis is a vascular disease [review]. Arthritis Rheum 2013; 65: 1953 - 62.
dc.identifier.citedreferenceAvouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies [review]. J Rheumatol 2010; 37: 2290 - 8.
dc.identifier.citedreferenceNihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long- term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625 - 35.
dc.identifier.citedreferenceLefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis- associated pulmonary hypertension: a systematic review and meta- analysis. Arthritis Rheum 2013; 65: 2412 - 23.
dc.identifier.citedreferenceSobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, et al. Characteristics and survival of anti- U1 RNP antibody- positive patients with connective tissue disease- associated pulmonary arterial hypertension. Arthritis Rheumatol 2016; 68: 484 - 93.
dc.identifier.citedreferenceCoghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence- based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340 - 9.
dc.identifier.citedreferenceKhanna D, McLaughlin V. Screening and early detection of pulmonary arterial hypertension in connective tissue diseases: it is time to institute it! Am J Respir Crit Care Med 2015; 192: 1032 - 3.
dc.identifier.citedreferenceYoung A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, et al. Update of screening and diagnostic modalities for connective tissue disease- associated pulmonary arterial hypertension. Semin Arthritis Rheum 2019; 48: 1059 - 67.
dc.identifier.citedreferenceMihai C, Antic M, Dobrota R, Bonderman D, Chadha- Boreham H, Coghlan JG, et al. Factors associated with disease progression in early- diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis 2018; 77: 128 - 32.
dc.identifier.citedreferenceSteen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516 - 22.
dc.identifier.citedreferenceKlinger JR, Elliott G, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults 2018: update of the CHEST guideline and expert panel report. Chest 2019; 155: 565 - 86.
dc.identifier.citedreferencePan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta- analysis. Clin Exp Rheumatol 2018; 36: 1095 - 102.
dc.identifier.citedreferenceNicolls M, Badesch D, Chung L, Domsic R, Medsger T, Pinckney A, et al. Safety and efficacy of B- cell depletion with rituximab for the treatment of systemic sclerosis- associated pulmonary arterial hypertension in a multi- center NIH clinical trial [abstract]. Arthritis Rheumatol 2019; 71 Suppl 10. URL: https://acrab- strac- ts.org/abstr- act/safety-and-effic- acy-of-b-cell-deple- tion-with-ritux- imab-for-the-treat- ment-of-syste- mic-scler- osis-assoc- iated-pulmo- nary-arter- ial-hyper- tensi- on-in-a-multi-center-nih-clini- cal-trial/.
dc.identifier.citedreferenceZamanian R, Badesch D, Chung L, Domsic R, Medsger T, Pinckney A, et al, on behalf of the Asco1 Investigators. Safety and efficacy of B- cell depletion with rituximab for the treatment of systemic sclerosis- associated pulmonary arterial hypertension. Eur R J 2019; 54 Suppl 63. URL: https://erj.ersjournals.com/content/54/suppl_63/RCT1884.
dc.identifier.citedreferenceAvouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70: 476 - 81.
dc.identifier.citedreferenceFlavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon [review]. Nat Rev Rheumatol 2015; 11: 146 - 58.
dc.identifier.citedreferenceKoenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty- year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902 - 12.
dc.identifier.citedreferenceMatucci- Cerinic M, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Cornelisse P, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long- term results from the DUO Registry. Ann Rheum Dis 2016; 75: 1770 - 6.
dc.identifier.citedreferenceHerrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O’Connell D, et al. Modified- release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011; 63: 775 - 82.
dc.identifier.citedreferenceHachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo- controlled SEDUCE study. Ann Rheum Dis 2016; 75: 1009 - 15.
dc.identifier.citedreferenceKorn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985 - 93.
dc.identifier.citedreferenceMatucci- Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS- 2 randomised, double- blind, placebo- controlled trial. Ann Rheum Dis 2011; 70: 32 - 8.
dc.identifier.citedreferenceWigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 1407 - 14.
dc.identifier.citedreferenceWigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo- controlled, double- blind study. Ann Intern Med 1994; 120: 199 - 206.
dc.identifier.citedreferenceSteen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352 - 7.
dc.identifier.citedreferenceJaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One 2016; 11: e0163894.
dc.identifier.citedreferenceSteen VD, Medsger TA Jr. Long- term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600 - 3.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 - 66.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma- related interstitial lung disease (SLS II): a randomised controlled, double- blind, parallel group trial. Lancet Respir Med 2016; 4: 708 - 19.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann- Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis- related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol 2017; 69: 1451 - 60.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41246_am.pdf
Size:
338.6KB
Format:
PDF
View/Open
Name:
art41246.pdf
Size:
677.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.